Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients

Investigators analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia, treated with Axicabtagene-Ciloleucel, Tisagenlecleucel, or Brexucabtagene autoleucel.